Stock Analysis, Dividends, Split History

ATW / Atwood Oceanics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)750.67
Enterprise Value ($M)1,574.49
Book Value ($M)3,399.82
Book Value / Share42.21
Price / Book0.22
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 64,799,000
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 64,805,914
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.06
Return on Equity (ROE)0.09
Balance Sheet (mrq) ($M)
Quick Ratio7.45
Current Ratio8.79
Income Statement (mra) ($M)
Sales Revenue Net1,020,644,000.00
Reimbursement Revenue44,296,000.00
Revenue Oil And Gas Services976,348,000.00
Operating Income294.28
Net Income265.27
Earnings Per Share Diluted4.09
Earnings Per Share Effectof Dilutive Securitieson Basic Earnings Per Share Restricted Stock0.00
Earnings Per Share Basic4.09
Cash Flow Statement (mra) ($M)
Cash From Operations625.01
Cash from Investing-202.94
Cash from Financing-202.94
Identifiers and Descriptors
Central Index Key (CIK)8411
Related CUSIPS
050095908 050095958

Split History

Stock splits are used by Atwood Oceanics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

18h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

KEG's Price Has Outrun Its Short-Term Fundamental Strength

2018-09-17 seekingalpha
Key Energy Services (KEG) is an onshore, rig-based well servicing contractor. In 2018 so far, KEG’s stock price has increased by 12%, and strongly outperformed the VanEck Vectors Oil Services ETF (OIH) which declined by 9% during this period. OIH represents the oilfield equipment & services (or OFS) industry. KEG piggybacks on the U.S. crude oil production growth and hydraulic fracturing revolution, even though the specter of the 2014-16 crude oil price crash haunts it. (4-0)

Transocean’s Acquisition Is a Mixed Bag

2018-09-12 investorplace
Left for dead. That’s the only way to describe the offshore drilling sector. For Transocean (NYSE:RIG) and its peers, years of low oil prices resulted in very low stock prices. And in many cases offshore drilling players filed for bankruptcy. So when there is any positive news about the sector, investors go gaga. That’s what happened when RIG announced its buyout of its struggling rival, Ocean Rig (NASDAQ:ORIG).

Transocean: Love Industry Consolidation

2018-09-05 seekingalpha
The deal further consolidates the industry into a few strong players that typically sets up a rally. (10-0)

Transocean Ups its Offshore Game, to Buy Ocean Rig for $2.7B

2018-09-05 zacks
Banking on the crude rally, if there is one industry that is ready for more consolidations, it is the offshore drilling space. In this regard, the offshore drilling giant Transocean Limited (RIG - Free Report) recently inked a deal to acquire smaller rival Ocean Rig UDW, Inc. in a $2.7-billion deal. Shares of Ocean Rig rallied 12% post the announcement of the deal. Ocean Rig’s joining hands with one of the largest offshore drillers and receiving a premium of more than 19% on its stock holdings boosted investors’ confidence in the stock. (47-0)

SEC Ends Investigation On Ensco DS-5 Contract

2018-09-05 seekingalpha
I look at the former Atwood fleet to find out how the acquisition has worked out for Ensco so far.

CUSIP: 050095108